HUP0203657A2 - Heterociklusos vegyületek és eljárások a szívgyengeség és más rendellenességek kezelésére - Google Patents

Heterociklusos vegyületek és eljárások a szívgyengeség és más rendellenességek kezelésére

Info

Publication number
HUP0203657A2
HUP0203657A2 HU0203657A HUP0203657A HUP0203657A2 HU P0203657 A2 HUP0203657 A2 HU P0203657A2 HU 0203657 A HU0203657 A HU 0203657A HU P0203657 A HUP0203657 A HU P0203657A HU P0203657 A2 HUP0203657 A2 HU P0203657A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
optionally
nrocr
conr2
Prior art date
Application number
HU0203657A
Other languages
English (en)
Inventor
John A. Lewicki
David Y. Lin
Babu J. Mavunkel
John J. Perumattam
George F. Schreiner
Original Assignee
Scios Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/128,137 external-priority patent/US6130235A/en
Priority claimed from US09/275,176 external-priority patent/US6340685B1/en
Application filed by Scios Inc. filed Critical Scios Inc.
Publication of HUP0203657A2 publication Critical patent/HUP0203657A2/hu
Publication of HUP0203657A3 publication Critical patent/HUP0203657A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A találmány tárgyát az (a) és (b) jelű általános képlettel jellemzettvegyületek és azok gyógyszerészetileg elfogadható sói képezik, ahol Z1és Z2 mindegyikének jelentése egymástól függetlenül CR4 vagy N; aholminden R4 jelentése egymástól függetlenül H vagy 1-6 szénatomos alkilvagy arilcsoport, mely alkil- vagy arilcsoportok tetszőlegesen egyvagy több heteroatomot tartalmaznak, mely O, S vagy N lehet, éstetszőlegesen egy vagy több halogénatom, OR, SR, NR2, RCO, COOR,CONR2, OOCR vagy NROCR szubsztituenst tartalmaznak, ahol R jelentésehidrogénatom vagy 1-6 szénatomos alkilcsoport, vagy egy vagy több CNvagy =O, vagy egy vagy több, tetszőlegesen 1-2 heteroatomot tartalmazóalifás vagy aromás 5- vagy 6-tagú gyűrű szubsztituensttartalmazhatnak; R1 jelentése az (I) általános képletű vegyület, aholX1 jelentése CO vagy annak egy izosztere; m értéke 0 vagy 1; Yjelentése tetszőlegesen szubsztituált alkil-, tetszőlegesenszubsztituált aril-, vagy tetszőlegesen szubsztituált arilalkil-csoport, vagy két Y együttesen egy 2-3 szénatomos alkilénhidatalkothat; n értéke 0, 1 vagy 2; Z3 jelentése CH vagy N; X2 jelentéseCH, CH2 vagy annak egy izosztere; és Ar egy vagy két fenilrészletbőláll, melyek közvetlenül kapcsolódnak az X2-csoporthoz, és amelyektetszőlegesen halogén-, nitro-, 1-6 szénatomos alkil-, 1-6 szénatomosalkenil-, 1-6 szénatomos alkinil-, CN- vagy CF3 szubsztituenst, vagyRCO, COOR, CONR2, NR2, OR, SR, OOCR vagy NROCR szubsztituensttartalmaznak, ahol R jelentése hidrogénatom vagy 1-6 szénatomosalkilcsoport, vagy fenilcsoport szubsztituenst tartalmaznak, mely magais tetszőlegesen a fent felsorolt szubsztituenseket tartalmazhatja; R2jelentése H, vagy 1-6 szénatomos alkil- vagy arilcsoport, mely alkil-vagy arilcsoportok mindegyike tetszőlegesen egy vagy több halogénatom,OR, SR, NR, RCO, COOR, CONR2, OOCR vagy NROCR szubsztituensttartalmazhat, ahol R jelentése hidrogénatom vagy 1-6 szénatomos alkil-vagy 1-6 szénatomos alkinilcsoport, vagy egy vagy több CN vagy =Oszubsztituenst tartalmazhat, vagy egy vagy több alifás vagy aromás 5-vagy 6-tagú gyűrűt, melyek tetszőlegesen 1-2 heteroatomottartalmaznak; R3 jelentése hidrogénatom, halogénatom, NO2, 1-6szénatomos alkil-, 1-6 szénatomos alkenil-, 1-6 szénatomos alkinil-,CN, OR, SR, NR2, RCO, COOR, CONR2, OOCR vagy NROCR csoport, ahol Rjelentése hidrogénatom vagy 1-6 szénatomos alkilcsoport. Ezek avegyületek a p38a kináz szelektív inhibitorai. Ó
HU0203657A 1998-05-22 1999-05-21 Heterocyclic compounds and methods to treat cardiac failure and other disorders HUP0203657A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8653198P 1998-05-22 1998-05-22
US09/128,137 US6130235A (en) 1998-05-22 1998-08-03 Compounds and methods to treat cardiac failure and other disorders
US09/275,176 US6340685B1 (en) 1998-05-22 1999-03-24 Compounds and methods to treat cardiac failure and other disorders
PCT/US1999/011222 WO1999061426A1 (en) 1998-05-22 1999-05-21 Heterocyclic compounds and methods to treat cardiac failure and other disorders

Publications (2)

Publication Number Publication Date
HUP0203657A2 true HUP0203657A2 (hu) 2003-03-28
HUP0203657A3 HUP0203657A3 (en) 2005-03-29

Family

ID=46203611

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203657A HUP0203657A3 (en) 1998-05-22 1999-05-21 Heterocyclic compounds and methods to treat cardiac failure and other disorders

Country Status (16)

Country Link
EP (1) EP1080078B1 (hu)
JP (1) JP2002516314A (hu)
KR (1) KR100605140B1 (hu)
CN (1) CN1229351C (hu)
AT (1) ATE316961T1 (hu)
AU (2) AU769465B2 (hu)
BR (1) BR9911069A (hu)
CA (1) CA2332459A1 (hu)
DE (1) DE69929689T2 (hu)
ES (1) ES2258331T3 (hu)
HK (1) HK1034707A1 (hu)
HU (1) HUP0203657A3 (hu)
NO (1) NO320299B1 (hu)
NZ (1) NZ508790A (hu)
PL (1) PL346345A1 (hu)
WO (1) WO1999061426A1 (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー.ディー.サール アンド カンパニー p38キナーゼ阻害剤としてのピラゾール誘導体
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
MXPA01002173A (es) * 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス,インコーポレーテッド p38キナーゼのインヒビターとしてのインドール型誘導体
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
WO2001064676A2 (en) * 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
ATE404553T1 (de) * 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
CA2429382A1 (en) * 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
CA2429605A1 (en) 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
EP1453515A4 (en) * 2001-11-09 2006-11-29 Scios Inc METHOD FOR TREATING CYSTIC FIBROSIS
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AU2003268464A1 (en) 2002-09-03 2004-03-29 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
PL376374A1 (en) 2002-10-09 2005-12-27 Scios Inc. Azaindole derivatives as inhibitors of p38 kinase
EP1633317A4 (en) 2003-05-16 2008-08-20 Intermune Inc Synthetic chemokine receptor ligands and methods of use therefor
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP5507049B2 (ja) 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2012026766A2 (ko) * 2010-08-25 2012-03-01 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3077499C (en) 2017-10-05 2021-09-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP3694528A4 (en) * 2017-10-13 2021-07-28 The Regents of the University of California MTORC1 MODULATORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179505A (en) * 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
JPH01230570A (ja) * 1987-11-25 1989-09-14 Takeda Chem Ind Ltd 抗paf剤および1,4−ジ置換ピペラジン化合物
US4937246A (en) * 1987-11-25 1990-06-26 Takeda Chemical Industries, Ltd. PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof
US5032598A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
JP2001506230A (ja) * 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
FR2753706B1 (fr) * 1996-09-20 1998-10-30 Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
JP2002515891A (ja) * 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds

Also Published As

Publication number Publication date
JP2002516314A (ja) 2002-06-04
CN1305464A (zh) 2001-07-25
AU4092099A (en) 1999-12-13
EP1080078B1 (en) 2006-02-01
NO320299B1 (no) 2005-11-21
CA2332459A1 (en) 1999-12-02
CN1229351C (zh) 2005-11-30
AU2004201809A1 (en) 2004-05-27
HK1034707A1 (en) 2001-11-02
WO1999061426A1 (en) 1999-12-02
EP1080078A1 (en) 2001-03-07
KR100605140B1 (ko) 2006-07-28
KR20010070946A (ko) 2001-07-28
NZ508790A (en) 2003-10-31
ATE316961T1 (de) 2006-02-15
NO20005881D0 (no) 2000-11-21
DE69929689T2 (de) 2006-11-02
DE69929689D1 (de) 2006-04-13
PL346345A1 (en) 2002-02-11
NO20005881L (no) 2001-01-09
ES2258331T3 (es) 2006-08-16
HUP0203657A3 (en) 2005-03-29
BR9911069A (pt) 2001-02-06
AU769465B2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
HUP0203657A2 (hu) Heterociklusos vegyületek és eljárások a szívgyengeség és más rendellenességek kezelésére
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0102723A2 (hu) Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
HUP9901403A1 (hu) Új benzotiofén-, benzofurán- és indolszármazékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300565A2 (hu) PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300138A2 (en) Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
HUP0302918A2 (hu) Mikrobaellenes oxazolidinonszármazékok és a vegyületeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0001446A2 (hu) HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
ES2188280T3 (es) Acetales heteroaril-ciclicos.
ES2195933T3 (es) Nuevos derivados de flavonas, xantonas y cumarinas.
EE04308B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
DE60027131D1 (de) Inhibitoren für asparagin-proteasen
HUP0104058A2 (hu) N-diszubsztituált piperazin vagy 1,4 diszubsztituált piperidin heterociklusos származékai és ezeket tartalmazó gyógyászati készítmények
KR920006322A (ko) 벤젠, 피리딘 및 피리미딘 유도체
NO964698L (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
CY1113359T1 (el) Αντι-νεοπλασιακα παραγωγα του et-743
ATE248147T1 (de) Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme
EA201000666A1 (ru) Производные 5-замещенных индол-3-карбоновой кислоты, обладающие противовирусной активностью, способ их получения и применение
HUP0303760A2 (hu) AZ NF-kB faktort gátló szubsztituált benzoesavszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP9900914A2 (hu) Simaizom sejtburjánzást gátló sztiril-benzimidazol-származékok
NO955197L (no) Nye carbosykliske nukleoside midler som er anvendbare som selektive inhibitorer av pro-inflammatoriske cytokiner
DK1161424T3 (da) Hidtil ukendte diazolderivater som serotonerge midler

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees